Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical has announced leadership changes following discussions with its largest shareholder, resulting in the immediate departure of Jeff Needham and James Barder from their roles as Non-Executive Chair and CEO, respectively. Alex Duggan, with over 25 years of experience in the consumer healthcare sector, will step in as Interim CEO, bringing a wealth of expertise to guide the company through a strategic review and potential growth opportunities. This transition is expected to impact Futura’s operations positively, as Duggan aims to leverage the company’s patented technology and product pipeline to maximize value for stakeholders.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £125.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in the research, development, and commercialization of topically delivered gel formulations, with their lead product, Eroxon®, addressing significant unmet needs in the erectile dysfunction (ED) market.
Average Trading Volume: 492,081
Technical Sentiment Signal: Sell
Current Market Cap: £23.84M
Find detailed analytics on FUM stock on TipRanks’ Stock Analysis page.